Literature DB >> 22937724

Assessing achievement and maintenance of glycemic control by patients initiating basal insulin.

Ning Wu1, Mark Aagren, Luke Boulanger, Michelle Friedman, Kelly Wilkey.   

Abstract

OBJECTIVE: Describe characteristics of diabetic patients who initiated basal insulin and assess their glycemic control. RESEARCH DESIGN AND METHODS: Physician encounters in the General Electric EMR Database (2005-2010) were assessed for patients with type II diabetes (T2DM) who initiated basal insulin between February 2006 and August 2009, with initiation defined as no prescription record of insulin in prior 15 months. Patients were followed for an average 2.5 years after insulin initiation. The proportion and time to achieving HbA1c ≤ 7% ('goal') were assessed. Among patients who reached goal, the proportion and time to HbA1c increasing above 7% were analyzed. Cox proportional hazard models were estimated to identify predictors of HbA1c goal achievement and goal sustainability.
RESULTS: Basal insulin initiators with T2DM (n = 13,373) were on average 60 years old, 50.5% were females, and 59.5% had HbA1c > 8%; 5840 (44%) patients reached goal within one year and 7699 (58%) reached goal during the ∼2.5-year follow-up. Being older, white or male, lower baseline HbA1c values, and no OAD use before insulin initiation were associated with significantly higher rates of reaching goal. Among patients who reached goal, 57.6% could not sustain the goal. Being Hispanic, higher baseline HbA1c values, and baseline OAD use were associated with significantly lower rates of goal sustainment.
CONCLUSION: A high proportion of T2DM patients did not have adequate glycemic control after initiating basal insulin. Various factors existing prior to insulin initiation were related to successful treatment of T2DM. Further research on how to improve glycemic control is encouraged.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22937724     DOI: 10.1185/03007995.2012.722989

Source DB:  PubMed          Journal:  Curr Med Res Opin        ISSN: 0300-7995            Impact factor:   2.580


  15 in total

Review 1.  Overbasalization: Addressing Hesitancy in Treatment Intensification Beyond Basal Insulin.

Authors:  Kevin Cowart
Journal:  Clin Diabetes       Date:  2020-07

2.  Dose Unit Establishment for a New Basal Insulin Using Joint Modeling of Insulin Dose and Glycemic Response.

Authors:  Yongming Qu; Junxiang Luo; Parag Garhyan; Caryl J Antalis; Annette M Chang; Scott J Jacober
Journal:  J Diabetes Sci Technol       Date:  2017-05-03

3.  A Randomized Controlled, Treat-to-Target Study Evaluating the Efficacy and Safety of Insulin Glargine 300 U/mL (Gla-300) Administered Using Either Device-Supported or Routine Titration in People With Type 2 Diabetes.

Authors:  Melanie Davies; Steve Bain; Guillaume Charpentier; Frank Flacke; Harmonie Goyeau; Michael Woloschak; Christoph Hasslacher; Giacomo Vespasiani; Steven Edelman
Journal:  J Diabetes Sci Technol       Date:  2019-01-15

4.  Glycemic and Cholesterol Control Versus Single-Goal Control in US Veterans with Newly Diagnosed Type 2 Diabetes: A Retrospective Observational Study.

Authors:  Lizheng Shi; Xin Ye; Mei Lu; Eric Q Wu; Hari Sharma; Darren Thomason; Mengxi Zhang; Yao Wang; Vivian A Fonseca
Journal:  Diabetes Ther       Date:  2015-07-23       Impact factor: 2.945

5.  Improvements in quality of life associated with biphasic insulin aspart 30 in type 2 diabetes patients in China: results from the A1chieve® observational study.

Authors:  Wenying Yang; Xiaoming Zhuang; Yukun Li; Qing Wang; Rongwen Bian; Jianguo Shen; Eva Hammerby; Li Yang
Journal:  Health Qual Life Outcomes       Date:  2014-11-26       Impact factor: 3.186

6.  Glycaemic control and hypoglycaemia burden in patients with type 2 diabetes initiating basal insulin in Europe and the USA.

Authors:  Dídac Mauricio; Luigi Meneghini; Jochen Seufert; Laura Liao; Hongwei Wang; Liyue Tong; Anna Cali; Peter Stella; Paulo Carita; Kamlesh Khunti
Journal:  Diabetes Obes Metab       Date:  2017-04-10       Impact factor: 6.577

7.  Using observational data to inform the design of a prospective effectiveness study for a novel insulin delivery device.

Authors:  Michael Grabner; Yong Chen; Matthew Nguyen; Scott D Abbott; Ralph Quimbo
Journal:  Clinicoecon Outcomes Res       Date:  2013-09-23

8.  The association of body mass index with the risk of type 2 diabetes: a case-control study nested in an electronic health records system in the United States.

Authors:  Michael L Ganz; Neil Wintfeld; Qian Li; Veronica Alas; Jakob Langer; Mette Hammer
Journal:  Diabetol Metab Syndr       Date:  2014-04-03       Impact factor: 3.320

9.  Persistence with Insulin Therapy in Patients with Type 2 Diabetes in France: An Insurance Claims Study.

Authors:  Ronan Roussel; Bernard Charbonnel; Mourad Behar; Julie Gourmelen; Corinne Emery; Bruno Detournay
Journal:  Diabetes Ther       Date:  2016-07-15       Impact factor: 2.945

10.  Benefits of combination of insulin degludec and liraglutide are independent of baseline glycated haemoglobin level and duration of type 2 diabetes.

Authors:  H W Rodbard; J B Buse; V Woo; T Vilsbøll; I H Langbakke; K Kvist; S C L Gough
Journal:  Diabetes Obes Metab       Date:  2015-11-05       Impact factor: 6.577

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.